|
Paket Informasi Teknologi |
| CLINICAL AND BIOLOGIC ACTIVITY OF AN ESTROGENIC HERBAL
COMBINATION (PC-SPES) IN PROSTATE CANCER |
| ROBERTS. DIPAOLA, M.D., HUAYAN ZHANG, M.D., GEORGE H. LAMBERT, M.D., R
ROBERT MEEKER, B.S., EDWARD LICITRA, PH.D., MOHAMED M. RAFI, PH.D., BAOTING ZHU, PH.D., HEIDI
SPAULDING, R.N.,SUSAN GOODIN, PHARM.D., MICHELB. TOLEDANO, M.D., WILLIAM N. HAIT, M.D., |
| |
| |
| Abstract |
| |
| Background: Herbal mixtures are popular alternatives to demonstrated therapies. PC-SPES, a commercially available combination of eight herbs, is used as a nonestrogenic treatment for cancer of the prostate. Since other herbal medicines have estrogenic effects in vitro, we tested the estrogenic activity of PC-SPES in yeast and mice and in men with prostate cancer.
Methods: We measured the estrogenic activity of PC-SPES with transcriptional-activation assays in
yeast and a biologic assay in mice. We assessed the clinical activity of PC-SPES in eight patients with hormone-sensitive prostate cancer by measuring serum prostate-specific antigen and testosterone concentrationsduring and after treatment. Results In complementary yeast assays, a 1:200
dilution of an ethanol extract of PC-SPES had estrogenic activity similar to that of 1 nM estradiol, and in
ovariectomized CD-1 mice, the herbal mixture increased uterine weights substantially. In six of six men
with prostate cancer, PC-SPES decreased serum testosterone concentrations (P<0.05), and in eight of
eight patients it decreased serum concentrations of prostate-specific antigen. All eight patients had breast tenderness and loss of libido, and one had venous thrombosis. High-performance liquid chromatography, gas chromatography, and mass spectrometry showed that PC-SPES contains trogenic organic compounds that are distinct from diethylstilbestrol, estrone, and estradiol.
Conclusions PC-SPES has potent estrogenic activity. The use of this unregulated mixture of herbs
may confound the results of standard or experimental therapies and may produce clinically significant
adverse effects. |
| |
| Source : |
N Engl J Med 1998;339:785-91 |
| |
| |
|
|